Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of chronic phase chronic myelogenous leukemia
• •* Philadelphia chromosome positive
• •Peripheral blast count no greater than 10%
• •No molecular remission
• •Less than 3 years since initial diagnosis
• •No anticipation of requirement for bone marrow or stem cell transplantation for 6 months
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-1
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Hemoglobin at least 10 g/dL
• •Platelet count at least 20,000/mm\^3
• •Hepatic:
• •Bilirubin less than 2.0 times upper limit of normal (ULN)
• •Transaminase less than 2.0 times ULN
• •Renal:
• •Creatinine less than 2.0 mg/dL
• •Other:
• •Not pregnant
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No significant active infection requiring hospitalization
• •No other serious illness or significant behavioral or psychological problem that would preclude study involvement
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •See Disease Characteristics
• •Prior interferon alfa allowed
• •No concurrent interferon alfa
• •Chemotherapy:
• •Prior cytarabine or other cytotoxic agents allowed
• •No concurrent cytarabine or other cytotoxic agents
• •Concurrent hydroxyurea allowed
• •Endocrine therapy:
• •No concurrent corticosteroid therapy
• •Radiotherapy:
• •Not specified
• •Surgery:
• •Not specified
• •Other:
• •No concurrent immunosuppressive medications
• •Concurrent imatinib mesylate allowed